About AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals is a Healthcare company based in Vienna (Austria) founded in 1996, and was acquired by Elan in May 2013. Develops, produces and distributes innovative drugs and administration methods for rare diseases. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified.
Company details
Founded in 1996 in Vienna, Austria, the company focuses on the pharmaceutical sector, particularly orphan drugs for rare diseases. Research, development, production, and distribution of specialized products occur in areas such as hematology, oncology, cardio-pulmonology, neurology, psychiatry, and metabolicgenetic disorders. A product pipeline is maintained for upcoming therapies, including treatments for tachycardia and polycythemia vera. Operations span all five continents, with branch offices in core European and Middle Eastern markets.
- Headquarters Vienna, Austria
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website aoporphan.com
- Social LinkedIn Facebook
- Acquired by Elan (May 2013)
Investors in AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of OTC products, prescription pharmaceuticals, nutritional products, and APIs | 1969 | elan.com | Dublin, Ireland |
Investor details for AOP Orphan Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AOP Orphan Pharmaceuticals
2 dated milestones of AOP Orphan Pharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.
- Founded AOP Orphan Pharmaceuticals is founded.
- Exit Acquired by Elan.
Web traffic of AOP Orphan Pharmaceuticals
Websites that share an audience with AOP Orphan Pharmaceuticals (aoporphan.com).
Websites whose visitors overlap most with AOP Orphan Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agtc.com | 100% | View details | |||
alxn.com | alxn.com | 94% | – | ||
orpha.net | orpha.net | 59% | #75,870 | – | |
| raredis.org | 58% | 8.1K | #2,990,876 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aop Orphan Pharmaceuticals
Complete news archive for AOP Orphan Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals was founded in 1996.
AOP Orphan Pharmaceuticals is headquartered in Vienna, Austria.
Founded in 1996 in Vienna, Austria, the company focuses on the pharmaceutical sector, particularly orphan drugs for rare diseases. Research, development, production, and distribution of specialized products occur in areas such as hematology, oncology, cardio-pulmonology, neurology, psychiatry, and metabolicgenetic disorders. A product pipeline is maintained for upcoming therapies, including treatments for tachycardia and polycythemia vera. Operations span all five continents, with branch offices in core European and Middle Eastern markets.
AOP Orphan Pharmaceuticals has 1 investor. Key investors include Elan.
Yes. AOP Orphan Pharmaceuticals was acquired by Elan in May 2013.